Regulus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Regulus Therapeutics

10/11/2022 22:01

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 50 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 49 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 50 cents​.
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Regulus Therapeutics Inc shares had fallen by 2.9% this
quarter and lost 47.6% so far this year.
    * The company reported a quarterly loss of $7.55 million.
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $14.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.49          -0.50          Missed
 Jun. 30 2022      -0.48          -0.50          Missed
 Mar. 31 2022      -0.53          -0.50          Beat
 Dec. 31 2021      -0.67          -0.70          Missed